You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》瑞銀上調康方生物-B(09926.HK)目標價至29.1元 評級「買入」
康方生物-B(09926.HK)公布自主研發的PD -1/CTLA-4雙特異性抗體腫瘤免疫治療新藥開坦尼(卡度尼利單抗注射液)的新藥上市申請已獲內地批准,用於治療既往接受含鉑化療治療失敗的復發或轉移性宮頸癌患者。 瑞銀發表報告指,該藥的定價和患者協助計劃詳情將於7月9日披露,相信是次的批准及時,可使該藥能夠參與即將開始的今年國家醫保目錄談判。基於良好的療效和安全性,該行期待該藥的適應症擴展至其他腫瘤類型,估計該藥於內地經風險調整的銷售額為34億元人民幣。 瑞銀上調康方生物股份目標價,由26.68元升至29.1元,評級維持「買入」。(ek/u) ~
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account